Yifeng Pharmacy Chain Co., Ltd. is a pharmaceutical retail company in China, operating through retail and wholesale segments. It offers Western and Chinese patent medicines, traditional Chinese medicine herbal pieces, medical devices and equipment, health supplements, personal care products, drugs, and health-related convenience products. The company is also involved in chronic disease management, medical project investment, and medical technology development, and operates internet hospitals and clinics. Founded in 2001 and headquartered in Changsha, China, it also sells through franchise distribution and e-commerce.
Yifeng buybacks, dividend and steady H1 profit growth lift the stock
▲
Company starts buying back its own shares Yifeng said it will spend 200-300 million yuan buying back its own stock at up to 30.56 yuan a share, to fund employee incentives. By early August it had already bought 1.78 million shares for 39.62 million yuan. Buybacks shrink the shares outstanding and signal management thinks the stock is cheap.
The buyback is the main new capital action supporting the price this period.
First-half profit grew faster than sales First-half revenue rose 3.5% to 12.13 billion yuan and net profit rose about 9.5% to 964 million yuan, helped by cost cuts. The company kept opening stores, ending with 15,239 outlets. Profit growing faster than sales shows the core pharmacy business is still healthy.
The interim results are the fundamental driver behind the stock's move.
Cash dividend announced alongside results Yifeng plans to pay 0.3 yuan per share in cash, about 363 million yuan, or 37.6% of first-half profit. A payout of that size returns real cash to shareholders and supports the shares, though it also means less money kept inside the company for expansion.
The dividend is a new shareholder-return event that supports the price.
Buyback wave shows industry capital returning Yifeng's buyback is part of a broad wave of Shanghai-listed companies buying back stock and insiders raising stakes, with 190 new buyback plans worth up to 55.5 billion yuan this year. This broad flow of company money into the market lifts sentiment for names like Yifeng.
It explains the wider market backdrop that amplifies Yifeng's own buyback.
Yifeng Pharmacy Chain reports 2026 interim net profit of 964 million yuan
Yifeng Pharmacy Chain has released its 2026 interim report. Total operating revenue was 12.13 billion yuan, and net profit attributable to the parent company was 964 million yuan. Net cash inflow from operating activities was 1.454 billion yuan, a decrease of 116 million yuan from the same period last year, down 7.40 percent year on year. The company's latest asset-liability ratio was 49.82 percent, gross margin was 40.30 percent, down 0.17 percentage points from the same period last year, and latest return on equity was 7.95 percent. Diluted earnings per share were 0.79 yuan, total asset turnover was 0.46 times, and inventory turnover was 1.66 times. The company had 22,800 shareholders, and the top ten shareholders held 746 million shares, accounting for 61.49 percent of total share capital.
603939.CG · Capital · Neutral Reports 2026 interim net profit of 964 million yuan, but no comparison to expectations or prior period, so impact unclear.
Yifeng Pharmacy Chain Plans Dividend of 0.3 Yuan Per Share, Totaling 363 Million Yuan
Yifeng Pharmacy Chain announced on August 27 that it plans to distribute a cash dividend of 0.3 yuan per share, before tax, to all shareholders, with an estimated total payout of 363 million yuan, accounting for 37.63% of net profit attributable to the parent company for the first half of 2026. In the first half of 2026, Yifeng Pharmacy Chain achieved revenue of 12.13 billion yuan and net profit attributable to the parent company of 964 million yuan.
Yifeng Pharmacy's first-half attributable net profit was approximately 964 million yuan, up 9.51% year on year
Yifeng Pharmacy released its 2026 semi-annual report, with first-half attributable net profit of approximately 964 million yuan, up 9.51% year on year. The company's first-half operating revenue was approximately 12.13 billion yuan, up 3.48% year on year. Yifeng Pharmacy is mainly engaged in the omni-channel retail business of Chinese and Western patent medicines, traditional Chinese medicine decoction pieces, medical devices, health foods and other products. The company said revenue growth was mainly driven by organic growth at existing stores and expansion of franchise distribution business, while net profit growth benefited from revenue growth and a decline in expense ratio brought by cost reduction and efficiency improvement.
Yifeng Pharmacy Chain Has Repurchased 1.78 Million Shares for 39.62 Million Yuan
Yifeng Pharmacy Chain announced that as of the disclosure date, it has repurchased 1.78 million shares, accounting for 0.15% of total share capital, with a total repurchase amount of 39.62 million yuan, at a price range of 22.01 yuan to 22.62 yuan per share. In the first quarter of 2026, the company achieved revenue of 6.085 billion yuan and net profit attributable to the parent company of 500 million yuan.
Shanghai-listed companies announce over 15 billion yuan in new buyback and shareholding increase plans in one week
Over the past week, Shanghai-listed companies launched 42 new buyback plans with a maximum value of 8.386 billion yuan, and 17 new shareholding increase plans with a maximum value of 7.457 billion yuan, marking a clear acceleration in industrial capital entering the market. The chairman of NARI Technology proposed a buyback of 500 million to 1 billion yuan worth of shares, the chairman of Daqin Railway proposed a buyback of 400 million to 500 million yuan, Sany Heavy Industry plans to repurchase A-shares worth 400 million to 800 million yuan, and Yifeng Pharmacy Chain plans to repurchase shares worth 200 million to 300 million yuan. On the shareholding increase side, the controlling shareholder of China Three Gorges Renewables plans to increase holdings by 1.5 billion to 3 billion yuan, the controlling shareholder of Aluminum Corporation of China plans to increase holdings by 1 billion to 2 billion yuan, and the controlling shareholder of China State Construction Engineering plans to increase holdings by 500 million to 1 billion yuan. Since the beginning of this year, Shanghai-listed companies have disclosed 190 new buyback plans with a total maximum value of 55.5 billion yuan, and 155 new shareholding increase plans with a total maximum value of 22.1 billion yuan.
600031.CG · Capital · Positive Sany Heavy Industry plans to repurchase A-shares worth 400-800 million yuan.
600406.CG · Capital · Positive Chairman of NARI Technology proposed a buyback of 500 million to 1 billion yuan.
601006.CG · Capital · Positive Chairman of Daqin Railway proposed a buyback of 400 million to 500 million yuan.
601600.CG · Capital · Positive Controlling shareholder of Aluminum Corp of China plans to increase holdings by 1-2 billion yuan.
601668.CG · Capital · Positive Controlling shareholder of China State Construction Engineering plans to increase holdings by 500 million to 1 billion yuan.
603939.CG · Capital · Positive Yifeng Pharmacy Chain plans to repurchase shares worth 200 million to 300 million yuan, a direct buyback plan.
Shanghai-Listed Companies Step Up Buybacks and Shareholder Increases This Year as Industrial Capital Continues to Flow In
A wave of share buybacks and shareholder increases continues to surge among companies listed on the Shanghai Stock Exchange, with the pace of industrial capital entering the market notably accelerating. Over the past week, 42 new buyback plans were added on the Shanghai market, with a maximum amount of 8.386 billion yuan, and 17 new shareholder increase plans were added, with a maximum amount of 7.457 billion yuan. Since the start of 2026, the Shanghai market has disclosed 190 new buyback plans, with a combined maximum amount reaching 55.5 billion yuan, and 155 new shareholder increase plans, with a maximum amount of 22.1 billion yuan. Many companies are making big moves. The chairman of NARI Technology proposed a buyback of 500 million to 1 billion yuan, the chairman of Daqin Railway proposed a buyback of 400 million to 500 million yuan, Sany Heavy Industry plans to buy back 400 million to 800 million yuan, and Yifeng Pharmacy Chain plans to buy back 200 million to 300 million yuan. The implementation of funds is also speeding up. Haier Smart Home has cumulatively bought back 1.817 billion yuan in this round, Seres has cumulatively bought back over 587 million yuan, Metallurgical Corporation of China has completed transactions totaling about 415 million yuan, and Chenguang Stationery has paid a total of 288 million yuan. On the shareholder increase side, the controlling shareholder of China Three Gorges Renewables plans to increase holdings by 1.5 billion to 3 billion yuan, the controlling shareholder of Aluminum Corporation of China plans to increase holdings by 1 billion to 2 billion yuan, and the controlling shareholder of China State Construction Engineering plans to increase holdings by 500 million to 1 billion yuan.
Yifeng Pharmacy Plans to Buy Back Shares Worth 200 Million to 300 Million Yuan
Yifeng Pharmacy announced plans to repurchase shares through centralized bidding, with the buyback amount set at no less than 200 million yuan and no more than 300 million yuan. The maximum repurchase price is 30.56 yuan per share, and the buyback period will not exceed six months from the date of board approval. In the first quarter of 2026, the company reported revenue of 6.085 billion yuan and net profit attributable to the parent company of 500 million yuan.
603939.CG · Capital · Positive Company announces share buyback of 200-300 million yuan, a capital allocation event that typically supports stock price.
Yifeng Pharmacy Plans to Repurchase 200 Million to 300 Million Yuan of Company Shares
Yifeng Pharmacy disclosed an announcement, planning to use its own funds to repurchase company shares through centralized competitive trading, for use in employee stock ownership plans or equity incentives. The amount for this share repurchase is 200 million to 300 million yuan, with a repurchase price not exceeding 30.56 yuan per share. The estimated number of shares to be repurchased is approximately 6.54 million to 9.82 million shares, accounting for about 0.54% to 0.81% of the company's total share capital. The repurchase period shall not exceed six months from the date the company's board of directors approves the share repurchase plan.
Yifeng Pharmacy Appoints Hu Jianxia as Vice President
Yifeng Pharmacy has appointed Hu Jianxia as Vice President. The company convened the Nomination Committee of the Board of Directors and the 31st meeting of the fifth Board of Directors on July 20, approving the appointment of Hu Jianxia as Vice President. She will concurrently cease to serve as Assistant President. Her term of office begins from the date of approval by this Board meeting and ends upon the expiry of the fifth Board of Directors' term. In the first quarter of 2026, Yifeng Pharmacy achieved revenue of 6.085 billion yuan and net profit attributable to the parent company of 500 million yuan.
China